Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.09M | $360.0M | 15.81% | +326.9K | 2026-06-30 |
| State Street Corp | 3.29M | $146.0M | 6.44% | +141.8K | 2026-06-30 |
| Congress Asset Management Co | 2.92M | $129.0M | 5.70% | +1.41M | 2026-06-30 |
| Vanguard Capital Management LLC | 2.26M | $100.0M | 4.41% | +25.0K | 2026-06-30 |
| Conestoga Capital Advisors, LLC | 2.08M | $92.0M | 4.07% | -379.5K | 2026-06-30 |
| William Blair Investment Management, LLC | 1.99M | $88.0M | 3.89% | +160.1K | 2026-06-30 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.64M | $72.0M | 3.20% | -83.6K | 2026-06-30 |
| GW&K Investment Management, LLC | 1.55M | $68.0M | 3.03% | -66.4K | 2026-06-30 |
| Soleus Capital Management, L.P. | 1.46M | $64.0M | 2.85% | -1.09M | 2026-06-30 |
| Geode Capital Management, LLC | 1.34M | $59.0M | 2.62% | +86.4K | 2026-06-30 |
